TAC defy drug patents
The Treatment Action Campaign (TAC) has challenged pharmaceutical giant Pfizer to take action against it for defying their patent on Fluconazole and importing the generic version from Thailand at a fraction of the cost of what it is being sold in South Africa.
Fluconazole prolongs the lives of people living with HIV/AIDS, especially those that develop thrush or cryptococcal meningitis.
TAC chairperson Zackie Achmat said a visit to Thailand exposed the “profiteering and patent abuse by Pfizer”.
He said a 200mg capsule of Fluconazole was being sold to the South African public sector at R28,57 and the private sector at R80,24 while the generic Thai capsule, a high quality version, could be purchased at a cost of R1,78 per capsule.
“We challenge Pfizer and the Pharmaceutical Manufacturers’ Association to take action against us. We will stop defying the unjust trade laws with Fluconazole once Pfizer has lowered the price to under R4 and its ‘donation’ is implemented with no restrictions,” said Achmat.
The “donation” Achmat referred to related to an announcement earlier this year by Pfizer that it would donate Fluconazole for cryptococcal meningitis free for all people living with HIV/AIDS. This followed pressure and challenges from the TAC.
Achmat has since accused Pfizer of making its donation a public relations exercise to disguise profiteering.
He said Pfizer had failed to finalise its agreement with the ministry of health, neither had it met the health ministers request for a lower price.
TAC said in a statement that it had begun to establish a network of doctors and pharmacists who would prescribe high quality, low cost generic medicines imported from countries such as Thailand and Brazil.
The group also urged Trade and Industry Minister Alec Erwin to give the full support of his ministry to the defiance campaign and Health minister Dr Manto Tshabalala-Msimang’s efforts to make healthcare accessible and affordable to all people.
The TAC again called on Glaxo Wellcome to reduce the price of AZT to R180 for 100 x 100mg tablets.
Author
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
You must include all of the links from our story, including our newsletter sign up link.
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
TAC defy drug patents
by Anso Thom, Health-e News
October 18, 2000